In rat liver, 6-oxidation of both VLCFA (1-3) and DA (4) occurs mostly in peroxisomes, only a minor fraction of these substrates being oxidized in mitochondria (3, 4).
CASE REPORTS
summarizes the clinical and biological data in the seven patients. More detailed clinical and histopathological data have been reported elsewhere (9, 10) . None of the patients had attack of drowsiness, vomiting, or episodes of hypoglycemia and acidosis during the course of the disease. The days before the study, all patients were eating a normal controlled diet providing a daily caloric intake of 100-120 kcal/kg, with 2.5 g/kg protein and 2 g/kg lipid. Estimated dietary intake of phytol was less than 1 mg/kg/day. Patients 1, 2, and 5 received Phenobarbital and patients 3 and 4, Carbamazepine.
MATERIALS AND METHODS
Reagents. Malonic, glutaric, 2-methylglutaric, phenylsuccinic, adipic, pimelic, suberic, azelaic, sebacic, undecanedioic, dodecanedioic, tetradecanedioic and hexadecanedioic acids, ethyl acetate and pyridine were obtained from Fluka (Buchs, Switzerland), tridecanedioic and n-butylmalonic acids from Aldrich (Beerse, Belgium), BSTFA with 1% TMCS from Pierce (Rockford, IL), and MTBSTFA with 1% TBDMCS from Chrompack (Middleburg, The Netherlands).
Methods. The concentration of carnitine in plasma and urine was measured using a slight modification of the method of McGarry (I 1). Plasma VLCFA were measured using a previously reported GC/MS technique (5) . FFA were analyzed as follows: 20 p1 plasma samples, obtained after overnight fasting, were added to I ml distilled water, then acidified with hydrochloric acid (1 2 mollliter). Nonadecanoic acid (50 pmol/liter) was added as internal standard, and FFA were extracted in ethyl acetate, evaporated to dryness under N2 and derivatized with MTBSTFAIpyridine (I: 1). C16:0, C16: 1, C18:0, C18: 1, and C18:2 FA concentrations were quantified by selected ion monitoring of their [M-571 ions. BOHB was measured from 50 plasma samples by ethyl acetate extraction, esterification by BSTFAIpyridine (1:l) and selected ion monitoring of the [M-151 ion using malonic acid as internal standard.
ANALYSIS AND QUANTITATION OF URINARY ORGANIC ACIDS
Urine samples were collected after overnight fasting, immediately frozen and kept at -8O"C until analysis. Creatinine was determined on a Astra 8 apparatus (Beckman, Brea, CA).
The extraction of organic acids was performed with slight modifications of a previously described technique (1 2): 2-methylglutaric, n-butylmalonic, and phenylsuccinic acids were added as internal standards to a volume of urine containing 1.5 to 4 pmol of creatinine, extracted in ethyl acetate, evaporated to dryness and dissolved in 100 p1 of a BSTFAIpyridine (1:l) mixture.
Urinary organic acids were separated on a Girdel (Suresnes, France) model 30 gas chromatograph coupled with a quadrupole mass spectrometer R 10-10 B (Nermag, Rueil-Malmaison, France) equipped with a PDP 8a computer system (Digital Equipment) with a Sidar data system (Nermag). The chromatographic resolution of organic acids was obtained on a CPSil 5 (25 m x 0.25 mm) silica fused capillary column (Chrompack) using helium carrier gas (2 ml/mn) with a Ross injector, the temperature of which was programmed from 110 to 240°C (5"/min). Mass spectrometer conditions were as follows: electron energy, 70 eV; source temperature, 180°C; emission current, 0.2 mA; mass range: 50-550 amu; mass integration: I ms/amu; delay between scan: 0.2 s. The molecular weight of unusual products was determined by chemical ionization with ammonia (2 X 10-4 Torr). The quantification of organic acids was obtained by measurement of the [M-151 ions.
RESULTS Figure 1 shows the profile of organic acids excreted in the urines of a patient with ZS, patients with NALD presenting a similar pattern. The most prominent characteristic is the presence of DA of various chain length ranging from adipic (C6) to hexadecanedioic ((216) acids. More precisely, three groups of compounds were observed: 1) even-numbered DA with medium (adipic, suberic and sebacic acids) and long-chain (hexadecanedioic acid); 2) odd-numbered DA with medium (pimelic and azelaic acids) and long-chain (undecanedioic, tridecanedioic and pentadecanedioic acids); and 3) medium-chain hydroxy-DA (2-and 3-hydroxy-sebacic acids). Several DA were accompanied by the corresponding unsaturated analogue. Quantitation of most of these products is presented in Table 2 .
We identified compound 29 in Figure 1 as 2-hydroxy-sebacic acid since it has the same retention time (methylene unit: 20.30) and mass spectrum (Fig. 2) as the pure compound obtained by synthesis.
Products 1 I, 19, and 26 in Figure 1 were thought to represent unsaturated DA with 7, 9, and 11 carbon atoms, respectively. In the absence of available pure compounds, this was based on the analysis of their mass spectra (Fig. 3) and on the comparison of the retention times and molecular weights of these unsaturated DA with those of the corresponding saturated homologues. The ratio of the [M-151 ion of each unsaturated product to its saturated homologue was in a range of 0.25-1, an abnormally high value indicating an excess of the unsaturated forms.
Product 3 1 of Figure I was identified as tridecanedioic acid, since its retention time and mass spectrum (Fig. 4A) were iden- Fig. I . Urinary organic acid profile of case 1. The peaks are identified as the TMS derivatives of the following acids: 1, 3-hydroxy-butyric; 2,2-hydroxy-isocaproic; 3, succinic; 4, fumaric; 5, glutaric; 6, 2-methylglutaric (internal standard); 7, n-butylmalonic (internal standard); 8, adipic; 9, 3-methyladipic; 10, 2-hydroxy-glutaric; 11, unsaturated pimelic; 12, pimelic; 13, 4-hydroxy-phenylacetic; 14 and 15, unsaturated suberic; 16, suberic; 17, phenylsuccinic (internal standard); 18, homovanillic and aconitic; 19, unsaturated azelaic; 20, azelaic; 21, hippuric; 22, citric; 23, vanylmandelic and unsaturated sebacic; 24, sebacic; 25, 4-hydroxyphenyllactic; 26, unsaturated undecanedioic (*); 27, undecanedioic; 28, 4-hydroxy-phenylpyruvic; 29, 2-hydroxy-sebacic; 30, 3-hydroxy-sebacic; 3 1, tridecanedioic; 32, hydroxy-hippuric; 33, 3-hydroxy-dodecanedioic (*); 34, pentadecanedioic; 35, hexadecanedioic (*). The column used was 25 m X 0.2 mm silica fused capillary column with CPSil 5 and temperature programed at 5"/min from 1lO"C. TIC, total ion current versus scan number;*, product not found in this patient, but present in other cases (retention time indicated by an arrow).
tical to that of the pure compound. Compound 34 was tentatively identified as pentadecanedioic acid on the basis of the relative retention time of this compound compared to that of added tetra-and hexadecanedioic acids, the analysis of its mass spectrum (Fig. 4B) , and its molecular weight [4 163 . DISCUSSION Our patients with ZS and NALD excrete even-numbered free medium-chain DA (adipic, suberic, and sebacic acids), the two latter compounds being more abundant than adipic acid in 617 64 ROCCHICCIOLI ET A L cases (Table 2) , an observation consistent with that of Bjorkhem et al. (13) in two patients with ZS. The excretion of DA may result from the increased ketogenic activity of a liver supplied with relatively large amounts of FFA (1 4), or from an impairment of p-oxidation of FA in mitochondria and/or peroxisomes (1 5). Carnitine deficiency, which prevents LCFA to be transported inside mitochondria, thus a well-established cause of dicarboxylic aciduria (16), was excluded since the concentrations of carnitine in the plasma and urine of the patients were normal (table 1) .
The most prominent finding in the present study is the accumulation of odd-numbered DA including medium-chain (pimelic and azelaic) as well as long-chain (tri-and pentadecanedioic) acids. The excess of tri-and pentadecanedioic acids can result from two mechanisms (Fig. 5 ): 1) an increased synthesis of 2-hydroxy-VLCFA leading to odd-numbered VLCFA and 2) a decreased peroxisomal p-oxidation of odd-numbered VLCFA leading to an accumulation of w-oxidation products which are uncompletely p-oxidized.
2-Hydroxy-VLCFA originate mainly from brain, which contains large quantities of VLCFA (C22-C26) as components of myelin cerebrosides and sulfatides (17) . These VLCFA undergo a-oxidation, i.e. hydroxylation on the a-carbon, in microsomes (1 [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] , then oxidative decarboxylation, giving a FA containing one fewer carbon atom. The synthesis of hydroxy-FA increases rapidly during the myelination period (23), the hydroxylation system being induced during brain development by an increased production of non-hydroxy-VLCFA (20) . The accumulation of VLCFA in brain, adrenal glands, and plasma in patients with ZS and NALD (8) is thus likely to induce increased levels of 2-hydroxy-analogues. Indirect evidence of the increase of 2-hydroxy-VLCFA in the tissues is the accumulation of odd-numbered-VLCFA (C23:O and C25:O) in the plasma of these patients (7) . Since there is a strong evidence that the peroxisomal catabolism of VLCFA is impaired in ZS and NALD (1-3) , oddnumbered VLCFA may rather be directed toward microsomal w-oxidation and lead to odd-numbered DA. These odd-numbered DA are then likely to accumulate if their P-oxidation in mitochondria and/or peroxisomes is impaired (Fig. 5) . Whereas 3-hydroxy-sebacic acid has been observed in defects of P-oxidation of medium-chain fatty acyl-CoA (12, 24) and in ketoacidosis (25) , the accumulation of 2-hydroxy-sebacic acid has not been reported in the urine of patients with inborn errors of metabolism. It may arise: 1) from the 2-hydroxylation and woxidation of LCFA and VLCFA and/or 2) from sebacic acid by analogy with the formation of 2-hydroxy-phytanic acid from phytanic acid in the liver (26) . The 2-hydroxy-sebacic acid may further be degraded by oxidative decarboxylation, leading to azelaic and pimelic acids (Fig. 5) .
The excess of monounsaturated DA may be related to the accumulation of monounsaturated VLCFA, specially C26: 1 which is largely increased in ZS and NALD (9) .
In conclusion, the accumulation of odd-numbered DA and 2-hydroxy-sebacic acid in ZS and NALD, together with increased plasma levels of VLCFA (5-8), phytanic acid (9), and pipecolic acid (27) , as well as the impairment of bile acids (28) and plasmalogens (29-31) synthesis, may be an additional useful markers in this group of peroxisomal disorders.
